Top

Published in:

01-12-2020 | Cystitis | Research article

Clinical efficacy of submucosal injection of triamcinolone acetonide in the treatment of type II/III interstitial cystitis/bladder pain syndrome

Authors: Tao Jiang, Xiaozhou Zhou, Zhipeng Chen, Tailin Xiong, Jian Fu, Zhengchao Liu, Dishi Yan, Zhansong Zhou, Wenhao Shen

Published in: BMC Urology | Issue 1/2020

Abstract

Background

To evaluate the efficacy of submucosal injection of triamcinolone acetonide for the treatment of type II/III interstitial cystitis/bladder pain syndrome.

Methods

A retrospective analysis of the clinical data of type II/III interstitial cystitis/bladder pain syndrome patients treated in our department from April 2016 to August 2018 was conducted, and changes in International Prostate Symptom Scores and the Pelvic Pain and Urgency/Frequency symptom scale after surgery were evaluated to explore factors that may affect patient outcomes.

Results

A total of 27 female patients and 8 male patients were enrolled, with type II patients accounting for 62.9% of the sample, and the median follow-up duration was 31 months (range: 12–40 months). Twenty-two patients (74.3%) had significantly improved questionnaire scores at 4 weeks postoperatively. Treatment efficacy was sustained for at least 1 year in 15 patients, and persistent effectiveness was noted in 10 (28.6%) patients. Patients with an advanced age (p = 0.015), high pain scores (p = 0.040), and higher International Prostate Symptom Scores (p = 0.037) and Pelvic Pain and Urgency/Frequency symptom scale scores (p = 0.020) were more likely to benefit from submucosal injection of triamcinolone acetonide. Gender, disease duration, and the presence of Hunner’s lesions had no predictive value for treatment outcomes.

Conclusion

Submucosal injection of triamcinolone acetonide can improve the clinical symptoms and quality of life in both men and women with type II/III interstitial cystitis/bladder pain syndrome. Patients with an advanced age and more severe interstitial cystitis/bladder pain syndrome related symptoms may benefit more from triamcinolone acetonide injection.

Available only for authorised users

Nickel JC, Tripp DA, Pontari M, Moldwin R, Mayer R, Carr LK, et al. Psychosocial Phenotyping in women with interstitial cystitis/painful bladder syndrome: a case control study. J Urol. 2010;183:167–72. https://doi.org/10.1016/j.juro.2009.08.133.CrossRefPubMed

van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53:60–7. https://doi.org/10.1016/j.eururo.2007.09.019.CrossRefPubMed

Hanno PM, Erickson D, Moldwin R, Faraday MM. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193:1545–53. https://doi.org/10.1016/j.juro.2015.01.086.CrossRefPubMed

Cox M, Klutke JJ, Klutke CG. Assessment of patient outcomes following submucosal injection of triamcinolone for treatment of Hunner’s ulcer subtype interstitial cystitis. Can J Urol. 2009;16:4536–40.PubMed

Rittenberg L, Morrissey D, El-Khawand D, Whitmore K. Kenalog injection into Hunner’s lesions as a treatment for interstitial cystitis/bladder pain syndrome. Curr Urol. 2017;10:154–6.CrossRef

Bahlani S, Moldwin R. Endoscopic lysis of bladder scar associated with Hunner’s lesions: a new technique. Asian J Urol. 2015;2:59–62. https://doi.org/10.1016/j.ajur.2015.04.008.CrossRefPubMedPubMedCentral

Yi T, Lv J, Fu Q, Jiang C, Li J, Lv T, et al. Efficacy and safety of transurethral cystoscopic fulguration in the treatment of refractory and non-ulcer interstitial cystitis/painful bladder syndrome. J Mod Urol. 2016;21:511–5.

Hillelsohn JH, Rais-Bahrami S, Friedlander JI, Okhunov Z, Kashan M, Rosen L, et al. Fulguration for Hunner ulcers: long-term clinical outcomes. J Urol. 2012;188:2238–41. https://doi.org/10.1016/j.juro.2012.08.013.CrossRefPubMed

van de Merwe JP. Interstitial cystitis and systemic autoimmune diseases. Nat Clin Pract Urol. 2007;4:484–91. https://doi.org/10.1038/ncpuro0874.CrossRefPubMed

10.

Alagiri M, Chottiner S, Ratner V, Slade D, Hanno PM. Interstitial cystitis: unexplained associations with other chronic disease and pain syndromes. Urology. 1997;49:52–7. https://doi.org/10.1016/S0090-4295(99)80332-X.CrossRefPubMed

11.

Soucy F, Gregoire M. Efficacy of prednisone for severe refractory ulcerative interstitial cystitis. J Urol. 2005;173:841–3. https://doi.org/10.1097/01.ju.0000153612.14639.19.CrossRefPubMed

12.

Bosch PC. A randomized, double-blind, placebo-controlled trial of Certolizumab Pegol in women with refractory interstitial cystitis/bladder pain syndrome. Eur Urol. 2018;74:623–30. https://doi.org/10.1016/j.eururo.2018.07.026.CrossRefPubMed

13.

Theoharides TC, Kempuraj D, Sant GR. Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. Urology. 2001;57:47–55. https://doi.org/10.1016/S0090-4295(01)01129-3.CrossRefPubMed

14.

Nordling J, Anjum F, Bade J, Bouchelouche K, Bouchelouche P, Cervigni M, et al. Primary evaluation of patients suspected of having interstitial cystitis (IC). Eur Urol. 2004;45:662–9. https://doi.org/10.1016/j.eururo.2003.11.021.CrossRefPubMed

15.

Clemens JQ, Mullins C, Ackerman AL, Bavendam T, van Bokhoven A, Ellingson BM, et al. Urologic chronic pelvic pain syndrome: insights from the MAPP research network. Nat Rev Urol. 2019;16(3):187–200.CrossRef

16.

Afari N, Buchwald D, Clauw D, Hong B, Hou X, Krieger JN, et al. A MAPP network case-control study of urological chronic pelvic pain compared with nonurological pain conditions. Clin J Pain. 2020;36:8–15.CrossRef

Title: Clinical efficacy of submucosal injection of triamcinolone acetonide in the treatment of type II/III interstitial cystitis/bladder pain syndrome
Authors: Tao Jiang
Xiaozhou Zhou
Zhipeng Chen
Tailin Xiong
Jian Fu
Zhengchao Liu
Dishi Yan
Zhansong Zhou
Wenhao Shen
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Cystitis
Cystitis
Pain Syndromes
Published in: BMC Urology / Issue 1/2020
Electronic ISSN: 1471-2490
DOI: https://doi.org/10.1186/s12894-020-00597-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Clinical efficacy of submucosal injection of triamcinolone acetonide in the treatment of type II/III interstitial cystitis/bladder pain syndrome

Abstract

Background

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml

Does urethral length affect continence outcomes following robot assisted laparoscopic radical prostatectomy (RALP)?

Myxoma of the renal pelvis masquerading pelviureteric stenosis: conservative limited resection with renal preservation: case presentation and literature review

Presepsin and procalcitonin as predictors of sepsis based on the new Sepsis-3 definitions in obstructive acute pyelonephritis

Can we treat bladder cancer with intravesical Bacillus Calmette-Guerin in patients with prior tuberculosis infection? A population-based cohort study

8q24 clear cell renal cell carcinoma germline variant is associated with VHL mutation status and clinical aggressiveness